Novo Nordisk's diabetes drug is now commercially available in China.
Victoza is a diabetes treatment option which effectively lowers blood sugar levels as well as weight with low risk of hypoglycaemia .
Victoza is now available in more than 39 countries worldwide.
Victoza is the first and only human glucagon-like peptide-1 (GLP-1) analogue which is 97% similar to endogenous human GLP-1. Like natural GLP-1, Victoza functions by stimulating the beta cells to release insulin only when blood sugar levels are high.
Due to this glucose-dependent mechanism of action, Victoza is linked with a low rate of hypoglycaemia.
In Europe Victoza is provided as treatment for type 2 diabetic adults to achieve glycaemic control.
In the USA, last January Victoza was approved as an addition treatment to diet and exercise to improve blood sugar control in adults with type 2 diabetes .
Novo Nordisk Launches Diabetes Drug Victoza in China
Mon, 10 Oct 2011
Recommended links
Diabetic Health Insurance for a Single PersonDiabetic Health Insurance for a Couple
Diabetic Health Insurance for a Family
Diabetic Health Insurance for a Single Parentt
BMI Calculator
Diabetes Guides
Diabetes Shop
Diabetic Travel Insurance
Diabetic Life Insurance
What Diabetic Health Insurance Covers
How Diabetes Private Medical Insurance Policies Work
Scientist identify new form of harmful cholesterol
Diabetes can Affect Sex Lives
Diabetes one of the chronic illnesses that are the major global killers, says report
Bariatric surgery shown to help diabetes patients
Diet Guides
ContentMain
